medication regimens and sensor devices. Despite its leadership in pharmaceutical products for diabetes, Sanofi is not a market leader in blood glucose meters and devices, with firms such as Abbott ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Sanofi insisted the sale would help Opella expand by bringing in a partner willing to invest in a market that has more in common with the consumer goods market than pure pharmaceutical drugs.

With the rising popularity of telehealth providers offering GLP-1 medications like Ozempic, the terminology can get confusing ...

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...

Among Sanofi’s rare disease drugs, new rare blood disorder drug Altuviiio, a once-weekly new class of factor VIII therapy for hemophilia A, recorded sales of €172 million in the third quarter ...

The company is banking on revenue from its Sanofi deal and vaccines in development ... Syamnath Future of Healthcategory Eli ...

PARIS--(BUSINESS WIRE)--Regulatory News: Sanofi and Orano Med ... regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates ...

The deal would allow Sanofi to focus on its more lucrative, but riskier, innovative drugs and vaccines, and CD&R to take a 50% controlling stake in a business that is home to brands such as ...

The deal would allow Sanofi to focus on its more lucrative, but riskier, innovative drugs and vaccines, and CD&R to take a 50% controlling stake in a business that is home to brands such as ...